{"name":"ResMed","slug":"resmed","ticker":"RMD","exchange":"NYSE","domain":"resmed.com","description":"ResMed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19. Resmed also provides software to out-of-hospital care agencies to streamline transitions of care into and between these care settings for seniors and their care providers.","hq":"San Diego, CA / Sydney, Australia","founded":0,"employees":"10600","ceo":"Michael Farrell","sector":"Medical Devices / Respiratory","stockPrice":231.81,"stockChange":5.76,"stockChangePercent":2.55,"marketCap":"$33.8B","metrics":{"revenue":2957013000,"revenueGrowth":11,"grossMargin":61.5,"rdSpend":331284000,"netIncome":1400723000,"cash":1417069056,"dividendYield":1.06,"peRatio":23,"fiscalYear":"FY2020"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-01","type":"earnings","headline":"ResMed Reports Fourth Quarter and Full Year 2023 Results","summary":"ResMed reported fourth quarter and full year 2023 results, with revenue of $1.4 billion and adjusted earnings per share of $1.35.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"deal","headline":"ResMed Acquires Brightree for $800 Million","summary":"ResMed acquired Brightree, a provider of home healthcare software and services, for $800 million.","drugName":"","sentiment":"positive"},{"date":"2023-06-01","type":"regulatory","headline":"ResMed Receives FDA Clearance for AirSense 11 CPAP Machine","summary":"ResMed received FDA clearance for its AirSense 11 CPAP machine, a new device for the treatment of obstructive sleep apnea.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOOEpTSVpsb1M1X05IeU96UXVGQ2hSZHVabl9IMFBNYkt0LVdEbWlHZ2loQWFaUEl3cl9pZXZXblViLXpiZkYyTl9BZ0Z4Q0E4X0RrN0FmU0stSFY0RVQ4N2V6dU01NUl2dXByVkFVQTV5UFBTeE1SVlV1Ujcydlp4WEVXUWF2N193UTlGNW1XVEtqMFpxSG93bHgxaHd4Q250SGlWd1d3?oc=5","date":"2026-02-16","type":"pipeline","source":"Market Index","summary":"ChartWatch ASX Scans: Cochlear, CSL, Pro Medicus, Telix Pharmaceuticals, Technology One, Rio Tinto - Market Index","headline":"ChartWatch ASX Scans: Cochlear, CSL, Pro Medicus, Telix Pharmaceuticals, Technology One, Rio Tinto","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOYzl5TFV1VXM1SzNPWHB3TGtyWHJSdE9Pb2xZZkloU1dzNnBrVmlBck5MR0ZJVHJfWXR0R0hnc2NPWmhGdVBRV2EzcEN5V0JvTkhnWXgydjdhRHlUa3hEZkFucjRIOFhEX3VyTlFKYVc1SGJhbnpDbGlLWlJqd2VoanRraDZMZmt4UkM2U1kyZjR5Z1lFSVlWTU9kZkRsTUdldFBuMlhWaVNfd3lsQ3ZlNU42VXVHLVotVWdr?oc=5","date":"2026-02-04","type":"earnings","source":"TradingView","summary":"The Top 5 Analyst Questions From ResMed’s Q4 Earnings Call - TradingView","headline":"The Top 5 Analyst Questions From ResMed’s Q4 Earnings Call","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxONV9vaVhpdTlXMWtfNXJIZ1VOdlBmcUxLT3lvZTlDTkttYkpWNWpueXpUS04ySnozSng1RHZoQmJKYVZJZXdnZzBxS0hLVDdhZ2JqSkZMZVNvVUJJczAwalZZbU1SaFZlb0p1cmZEQVZfLTFrUWo2cFhOcldWdE9Ic1Y2ajNhQ3ZCSUFESVMwMUlxdFRFZVhXU05TTDh0ODFHNjg1Zg?oc=5","date":"2026-02-01","type":"pipeline","source":"Seeking Alpha","summary":"ResMed: Facing A Potentially Dream-Disrupting Dose - Strong Sell - Seeking Alpha","headline":"ResMed: Facing A Potentially Dream-Disrupting Dose - Strong Sell","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNeTA1TU9kOE5RenVCcTgwaFRTT0VHYzNKbW1fbmZSTkZwVVMxWlBPaWFoVXloQnNWeUtaMlEzMW1NMkRGUFJJLUpxMXVvM29iTjRJcFc3LVRTOGxkOFlxdVBCTWNaVDJtY2hCRmdvYVlYMVNfZVhjMURFOXZGb3RmbUMya3NVbXBiRXBiNXYtYzFJQXhIVEVaU3dmZw?oc=5","date":"2026-01-30","type":"earnings","source":"Insider Monkey","summary":"ResMed Inc. (NYSE:RMD) Q2 2026 Earnings Call Transcript - Insider Monkey","headline":"ResMed Inc. (NYSE:RMD) Q2 2026 Earnings Call Transcript","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFBBRktsZ2w1MEEwTTFRcVhKMzNZck9kcHhDWGdEd2ZoeXJFbUpheUVockJJb0gwMTREUkEwMXpmTFZxR25OTlpJbDZmdi13VDdwd0E0dzZRYkN6XzhHajVvc3N1ZUZldWNyOU9USVNWTVc5RGZzTGhV?oc=5","date":"2026-01-29","type":"earnings","source":"Yahoo Finance","summary":"ResMed Inc (RMD) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations - Yahoo Finance","headline":"ResMed Inc (RMD) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNZ0htRmJERzFlXzl5dm1nOC1kUVJXNDgwYnhWc0VuT0lDQzNaYlREQ0lxMGtDUENVVl9INnd4SjBQcjJnX0xMZVVDWjBWaEpPYW81LTRrWUszNFp2ZkRBaFJzQU54RVF0bmxOZkJhTHk2eVMtc2pmZWdmM0l0RGZZNmJCa1hyS2RGanU0UUFlUmRzVTZQM2t4SW9GdWVEa2R6Vi1DVWdjazhydzhj?oc=5","date":"2025-11-11","type":"pipeline","source":"Stockhead","summary":"Health Check: Big Pharma vies for the fat rewards of the anti-obesity market - Stockhead","headline":"Health Check: Big Pharma vies for the fat rewards of the anti-obesity market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFB6WEhvM0YySUk4SzlYV2ZhWUtDNjdMZzdEd1J1NDdRNG8xbkI4WlhmZzZ4TV93X21vaFVWR01lMnpxZmhZemkxVlV4UzZsN1Ff?oc=5","date":"2025-10-31","type":"pipeline","source":"smallcaps.com.au","summary":"Insights: Resmed Inc (ASX:RMD) - smallcaps.com.au","headline":"Insights: Resmed Inc (ASX:RMD)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE82UDBvMG5XaHV6S1p4WC1mWDNvOU9NOHFzT29YbmstaWhOZm9XcS16aUpzTmVjLThhLTM5MHRTZFBJMzVKUWdIYW5JNGg5QzJZSFIzUzd0a0IyRzJ1NDhHb1BQeHBrOFJjY0czdm5jYnIxaVhTcXBJ?oc=5","date":"2025-10-30","type":"earnings","source":"Yahoo Finance","summary":"ResMed Inc (RMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations - Yahoo Finance","headline":"ResMed Inc (RMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOR0lOZEdxZ0N2SUEtWExiQnd4YUx5R25GYzR0NUtKaWdvR3FIQmlpclpmWkdhRlpGVXpIX2ZRcV8zR2pKWVlyc0ppVFhjRERMem04X2dYSmo1eXhUQUJuLTFCbWwzVWtoTDVCQ2IyaEhOY0FLSWZRUFhjcUk0OW5sdUdyQldBRzJJLThjTURBYkwwRFVVZjZJeEIwTzZ2QQ?oc=5","date":"2025-09-23","type":"pipeline","source":"ig.com","summary":"ASX 200 healthcare stocks: ResMed, CSL, and Telix Pharmaceuticals in focus - ig.com","headline":"ASX 200 healthcare stocks: ResMed, CSL, and Telix Pharmaceuticals in focus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNX0NfcXdleXBmMmZPNlBhUmVTZTFsMVpodzhPUlJrOGtLYXI0TG1QZ0FWeWJHVFZDZmZOUGVmMHc4Wm0zYkJuX3RYVC1QVTNyYzVMMGMtUEtiVXVLSWlydFhNOEk0bFlkQldVS2thQlFVSXRSMm5LOGpka3B5MDktV3dsOGlWLWtnRFhnWmV1ZF85aFpXZG9qUGF0WUF6MGFMSFpMVS1fQXZ0aHBtOXBwc051SQ?oc=5","date":"2025-04-24","type":"pipeline","source":"AFR","summary":"‘Tariff-exempt’ ResMed boosts US manufacturing - AFR","headline":"‘Tariff-exempt’ ResMed boosts US manufacturing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiT0FVX3lxTE85al9PNFY4TkRYbndySzY4ZXphZ21mMHpSM1JCbnFNZ0R5S0hlNWFtRVpNT2lhNUJ3dnhxOWpZT2RTcnZXVVBYcHA2RGxza0U?oc=5","date":"2024-01-08","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTEFVX3lxTE9TV2I1cFByc1FqYzBEcnF3YUVjTTFXTmJMb0piWEZKcjdIR2swUFlTVTNkMUh5VmFpSkZLMjNzd3prN05ZZTlGeE1FNXc?oc=5","date":"2021-09-15","type":"pipeline","source":"The Motley Fool","summary":"ResMed - RMD - Stock Price & News - The Motley Fool","headline":"ResMed - RMD - Stock Price & News","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Philips Healthcare","Masimo","Invacare"],"therapeuticFocus":["Sleep-Disordered Breathing","Respiratory"],"financials":{"source":"sec_edgar","revenue":2957013000,"revenuePeriod":"2020-06-30","revenueHistory":[{"value":2957013000,"period":"2020-06-30"},{"value":2606572000,"period":"2019-06-30"},{"value":2606572000,"period":"2019-06-30"},{"value":2340196000,"period":"2018-06-30"},{"value":2340196000,"period":"2018-06-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":331284000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":1400723000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":8174391000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":231.81,"previousClose":226.05,"fiftyTwoWeekHigh":293.81,"fiftyTwoWeekLow":201.84,"fiftyTwoWeekRange":"201.84 - 293.81","fiftyDayAverage":246.48,"twoHundredDayAverage":258.82,"beta":0.93,"enterpriseValue":32361254912,"forwardPE":19,"priceToBook":5.34,"priceToSales":6.27,"enterpriseToRevenue":6,"enterpriseToEbitda":15.98,"pegRatio":1.39,"ebitda":2024966016,"ebitdaMargin":37.5,"freeCashflow":1417400064,"operatingCashflow":1914493056,"totalDebt":847721024,"debtToEquity":13.4,"currentRatio":3.06,"returnOnAssets":14.7,"returnOnEquity":25.7,"analystRating":"","recommendationKey":"none","numberOfAnalysts":15,"targetMeanPrice":296.87,"targetHighPrice":345,"targetLowPrice":230,"dividendRate":2.4,"payoutRatio":0.22,"fiveYearAvgDividendYield":0.84,"exDividendDate":1770854400,"insiderHeldPercent":0.5,"institutionHeldPercent":68.7,"sharesOutstanding":145678401,"floatShares":144789763,"sharesShort":11845253,"shortRatio":11.77,"shortPercentOfFloat":8.1,"epsTrailing":10.1,"epsForward":12.18,"revenuePerShare":36.9,"bookValue":43.39,"officers":[{"age":53,"name":"Mr. Michael J. Farrell BE, MBA, SM","title":"CEO & Chairman"},{"age":83,"name":"Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScD","title":"Founder, Chair Emeritus & Non-Executive Director"},{"age":58,"name":"Mr. Brett A. Sandercock","title":"Chief Financial Officer"},{"age":67,"name":"Mr. Michael J. Rider","title":"Chief Legal Officer & Secretary"},{"age":48,"name":"Mr. Justin  Leong","title":"Chief Product Officer"},{"age":null,"name":"Mr. Alastair  Robertson","title":"Chief Information Officer"},{"age":null,"name":"Ms. Sallilyn  Schwartz","title":"Chief Investor Relations Officer"},{"age":null,"name":"Mr. Jim  Ellis","title":"Chief Compliance Officer"}],"industry":"Medical Instruments & Supplies","irWebsite":"http://www.resmed.com/in/investors/investors.html?nc=investors","website":"https://www.resmed.com","phone":"858-836-5000"}}